SCHEMBL1860848

SCHEMBL1860848

CCOC(=O)C1=CC2(CCC1S(=O)(=O)Nc1ccc(C(C)C)cc1Br)OCCO2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 5/20 0.42
P2RX4 Q99571 2/20 0.33
P2RX7 Q99572 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
RAB9A P51151 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 1/20 0.31
RECQL P46063 1/20 0.31
TP53 P04637 2/20 0.31
MAPT P10636 1/20 0.31
EGFR P00533 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1863950 0.90 TLR4 (0.44) TLR4SMN1; SMN2ALDH1A1NPSR1HPGD
SCHEMBL1865534 0.88 TLR4 (0.52) TLR4NPC1MAPTEGFR
SCHEMBL1865713 0.88 TLR4 (0.54) TLR4NPSR1MAPT
SCHEMBL1859769 0.86 TLR4 (0.42) TLR4SMN1; SMN2NPC1ALDH1A1CYP1A2
SCHEMBL1864104 0.83 TLR4 (0.54) TLR4SMN1; SMN2ALDH1A1NPSR1MAPT
SCHEMBL1867117 0.82 TLR4 (0.41) TLR4NPC1ALDH1A1HPGDRECQL
SCHEMBL1862876 0.81 TLR4 (0.39) TLR4SMN1; SMN2ALDH1A1RAB9ANPSR1
SCHEMBL1864126 0.81 TLR4 (0.54) TLR4TRPV1CYP1A2CYP2C9CYP2C19
SCHEMBL1864530 0.81 TLR4 (0.55) TLR4NPC1ALDH1A1RAB9AHPGD
SCHEMBL1863967 0.81 TLR4 (0.55) TLR4CYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF TLR4 29/4885P2RX4 4146/4885P2RX7 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.